Close

Masimo Corp. (MASI) names Katie Szyman as new CEO

January 21, 2025 4:04 PM EST

Today the Board of Directors of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer. of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo’s Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025.

Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman led the Critical Care product group at Edwards Lifesciences (“Edwards”), which was acquired by BD in a transaction that closed in September of 2024. Her appointment follows an extensive search process overseen by the Board with the assistance of executive recruitment firm Korn Ferry. During this process, the Board evaluated numerous internal and external candidates. The Board concluded that Ms. Szyman was the right choice given her successful track record of accelerating revenue growth by bringing new patient monitoring products to market, extensive experience leading and retaining top industry talent, and deep existing relationships within the sector.

While at Edwards, Ms. Szyman significantly accelerated revenue growth in the Critical Care product group through numerous successful initiatives, including entering adjacent markets through internal and external innovation and introducing the first AI technology cleared by the Food and Drug Administration in the patient monitoring space. She possesses significant operational and financial leadership experience that will aid Masimo as it continues to address its cost structure and improve gross margin performance. Ms. Szyman also brings public company board experience, including serving as a director of Inari Medical since 2019.

Mr. Koffey stated:

“Katie’s more than 35 years of relevant experience and her unique mix of expertise set her apart during our search and make her an ideal fit to lead the next innovation-focused stage of Masimo’s evolution. We also want to thank Michelle for her exemplary performance in the interim CEO role, particularly in leading a seamless transition for customers, employees and shareholders from day one. We look forward to continuing to benefit from her experience and judgment as she moves into her new position as Chairman of the Board.”

Ms. Brennan added:

“We wanted our next CEO to be someone who is passionate about the role and inspiring as well as engaging the team at Masimo – and Katie made clear that she is that person. Her advanced patient monitoring category knowledge and deep existing relationships within the industry position her to make an immediate impact as she works with the Board on prioritizing our pipeline to focus on large opportunities, while developing a clear strategy for bringing our next generation patient monitoring platform to market.”

Ms. Szyman commented:

“I have long admired Masimo as an innovation leader, and I could not be more excited about the opportunity to grow the business and deliver improved outcomes for millions more patients around the world. I believe Masimo’s leadership team and bench of talent is top tier, and I am thrilled by the chance to work with and learn from this group.”

The Board remains committed to the previously announced review of alternatives for both the consumer audio and consumer healthcare businesses and has engaged Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as a legal advisor. The Board looks forward to providing updates in the near-term regarding value-creation initiatives, including this strategic review.

More About Katie Szyman

Ms. Szyman led the Critical Care business at Edwards Lifesciences for over a decade – including through the acquisition by BD (Becton, Dickinson and Company) in September of 2024. While at Edwards, Ms. Szyman accelerated the revenue growth of the business by shifting to AI-driven solutions that aid clinicians in decision making and help patients return home to their families faster. Previously, Ms. Szyman spent more than 20 years at Medtronic, where she held positions with increasing levels of responsibility inside and outside the U.S., including leadership roles in corporate strategy, business development and finance, and as the worldwide president of both the Endovascular and Diabetes business units. Ms. Szyman currently serves on the board of Inari Medical (NASDAQ: NARI). She previously served on the boards of Outset Medical (NASDAQ: OM), the Edwards Lifesciences Foundation, and the Opus School of Business at the University of St. Thomas. Ms. Szyman received a B.A. from the University of St. Thomas and an M.B.A. from Harvard Business School.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Hot Corp. News, Hot Mgmt Changes, Management Changes

Related Entities

Morgan Stanley, Definitive Agreement, Maynard Um, Mark Zuckerberg, FDA, ARK